PFE Jan 2025 35.000 call
| Previous close | 1.1900 |
| Open | 1.2100 |
| Bid | 1.1800 |
| Ask | 1.2200 |
| Strike | 35.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.1800 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 31.25k |
Business WireMarstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
NEW YORK, December 10, 2023--Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (NCT03938792) evaluating marstacimab for the treatment of people with severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). The results from the BASIS trial demonstrated a statistically significant and clinically meaningful effect on annualized bleeding rate (ABR). The findings were presented today at t
Motley Fool3 Dividend Stocks Trading at 52-Week Lows
I have always stated that stocks should not be bought just because they trade at a 52-week low. A new 52-week low does not make a particular stock cheap. In today's video I will look at three dividend stocks trading at their 52-week lows and examine their metrics to determine if the stock is cheap or not.
Motley FoolIs Pfizer Stock a Buy Now?
Shares of Pfizer (NYSE: PFE) have been in an endless tailspin this year -- now down more than 40%. Revenue from its COVID-19 products is down big, and investors are concerned about looming patent cliffs for the business in the years ahead. Let's look at what happened -- and Pfizer's prospects for overcoming this latest challenge.
